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1. Introduction  
Hepatocellular carcinoma (HCC) is the third most common cause of cancer mortality 
worldwide and accounts for 20% of all liver transplants (Wigg, 2010). Its incidence has 
increased two fold in the last decade and it is the fifth leading cause of cancer in males. The 
availability of liver transplantation as a cure for chronic liver disease and the demonstration 
of outcomes exceeding 70% at 5 years after transplantation for HCC have pushed the field to 
refine this therapy in order to utilize this precious resource in the most effective, fair and 
safe manner. The combination of a rising incidence of HCC and a flat donor procurement 
rates has resulted in longer waiting times in many areas. The complex decision making and 
management issues of patients with HCC, cirrhosis and possibly undergoing oncological 
therapies while waiting for an organ transplant poses challenges to the management team, 
not encountered in any other clinical or surgical field. 
2. Epidemiology 
Hepatocellular carcinoma (HCC) accounts for 85% to 90% of the primary liver cancers (El-
Serag & Rudolph, 2007). The alarming results of epidemiologic studies performed over the 
last 2 decades have raised awareness, and shed light on its magnitude as a public health 
problem. Hepatoma is the fifth most common cancer worldwide, accounting for roughly 4% 
of all the new cancers diagnosed. It is currently the third most common cause of cancer-
related death in the world (Altekruse, 2009; Parkin, 2005). Recent data presented by the 
Center for Disease Control and Prevention has liver cancer listed as the ninth leading cause 
of cancer-related deaths in the United States. In addition, hepatocellular carcinoma has 
become one of the fastest growing causes of malignancy-related death in this North 
American country, and its overall age-adjusted incidence has also significantly increased 
over the last 20 years (El-Serag & Rudolph, 2007).  
The incidence of hepatocellular carcinoma differs depending on aspects such as geographic 
location, sex, age, race and ethnicity, environmental exposure to certain agents, as well as 
presence of other risk factors. In general, it has been clearly established that the vast 
majority of the cases of hepatocellular carcinoma occur in the setting of cirrhosis arising 
from chronic liver disease with approximately 80% of the cases due to chronic hepatitis B 
and hepatitis C infection (Perz, 2006). Sub-Saharan Africa and Eastern Asia, which are 
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endemic areas for hepatitis B, are considered among the regions with highest rate of 
hepatoma. The incidence for men is as high as 35.5/100,000 in China, where more than 50% 
of all hepatocellular carcinomas occur (El Serag & Rudolph, 2007, as cited in Parkin, 2002). 
Interestingly, a downtrend in the rate of hepatocellular carcinoma has been seen in several 
high risk Asian countries. The success of vaccination programs against hepatitis B may be 
one of the main factors contributing to this decrease (Chang et al., 2009). In contrast to most 
other Asian countries, Japan’s incidence of primary liver cancer is associated to chronic 
hepatitis C infection which came about after the rampant spread of this virus during the 
post-World War II years (Yoshizawa, 2002). Recent studies suggest that this incidence is also 
now decreasing (Tanaka et al., 2008). 
The rates of primary hepatic cancer in areas that are considered low risk are well below 10 
per 100,000. These include most of Europe, North and South America, Australia and New 
Zealand (Bosch, 2005). The risk factors for hepatoma in these geographic locations are 
somewhat different to Sub-Saharan and Asian countries with hepatitis C, alcohol and 
nonalcoholic fatty liver disease playing a pivotal role. In the United States, for example, the 
aging large population of chronic hepatitis C infected patients that progress to cirrhosis has 
caused a disturbing increase in the incidence of hepatocellular carcinoma over the last two 
decades (Davila, 2004, Kanwal, 2011). This trend has also been seen in other developed 
nations. In addition to the effect of chronic hepatitis C-related cirrhosis, these countries are 
experiencing growing problems with heavy alcohol consumption, as well as diabetes and 
obesity which are associated to nonalcoholic fatty liver disease, and could all lead to 
cirrhosis and liver cancer (Nordenstedt, 2010). 
2.1 Age and sex 
The rate of hepatocellular carcinoma is higher across the board in males than females. This 
has been well documented in multiple registries that looked at different populations 
affected by this cancer (Bosch et al., 2005). In general, the male to female ratios range 
between 2:1 and 4:1, with the larger variation seen in regions with higher and intermediate 
incidence of hepatoma. Interestingly, the discrepancy in rates is up to 5:1 in France (El-Serag 
& Rudolph, 2007). The grounds for this global disparity between men and women are not 
well understood, but several theories exist linking this phenomenon to differences in sex-
specific exposure to risk factors such as viral hepatitis, alcohol, and tobacco (Donato, 2002). 
The trophic effects of androgens have also been implicated (Yu et al., 2001). 
Hepatocellular carcinoma most commonly occurs in the presence of cirrhosis as a result of 
long standing chronic liver disease. In general, the process of inflammation and fibrosis that 
leads to cirrhosis usually takes many years, although it could be accelerated when more 
than one risk factor is affecting an individual. As a result, most cases of hepatoma are seen 
in older patients. The age at which the incidence of primary liver cancer peaks in high risk 
areas is typically lower than in areas of lesser risk, 50 to 60 years old and 70 to 75 years old, 
respectively. However, it is not uncommon to see hepatocellular carcinoma affecting people 
ages 20 to 35 in geographic locations of high incidence, and where factors such as chronic 
hepatitis B and aflatoxins, an environmental toxin and carcinogen, are endemic. Vertical 
transmission of hepatitis B with over 90% chronicity of infected persons, and early constant 
exposure to aflatoxins in these areas contribute to the earlier incidence of hepatoma (Bosch, 
2005).  
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2.2 Race and ethnicity 
The racial and ethnic variations seen in the incidence of hepatocellular carcinoma are 
influenced by the geographic distribution of this malignancy. Accordingly, the higher 
incidence is seen in individuals from Africa and Asia. The migratory patterns of populations 
moving from intermediate and high risk areas into developed countries, has contributed to 
change the frequency of primary liver cancer not only globally, but within people living in 
the same region. In the United States, for example, the highest age-adjusted rates of 
hepatocellular carcinoma are seen in Asians for both sexes (El-Serag & Rudolph, 2007). This 
group is followed in occurrence by Hispanics, African Americans and Caucasians. The 
marked growth in the Hispanic population over the last decade, making it the largest 
minority in the United States has also had an impact in the liver cancer demographics in this 
North American nation (El-Serag, 2007).  
2.3 Risk factors 
Several factors have been associated to hepatocellular carcinoma, being the most relevant 
viral hepatitis, alcohol, exposure to toxins and nonalcoholic fatty liver disease. In general, 
any etiology that causes chronic liver disease and that could lead to cirrhosis is a potential 
risk factor for primary liver cancer. It must be noted that hepatoma can very infrequently 
occur in the absence of cirrhosis as is the case of some individuals with chronic hepatitis B.  
2.3.1 Viral hepatitis 
Viral hepatitis, in particular chronic hepatitis B and C, account for over 80% of the cases of 
primary hepatic cancer. The degree of connection of these two viruses to hepatocellular 
carcinoma varies depending on the region being evaluated. Most of the hepatitis B-related 
hepatoma cases are seen in Africa and Asia, whereas most of the hepatitis C-related cases 
are seen in Europe, the United States and Japan (Bosch et al., 2004). Donato et al. and Shi et 
al. showed in their respective meta-analysis that chronic hepatitis B and C infection carry a 
significant risk for hepatoma. This risk was higher in co-infected patients with an odds ratio 
of 165 and 35.7 in their respective studies (Donato, 1998; Shi, 2005). Individuals with 
hepatitis B e antigen positivity have also shown to have an increased risk for primary liver 
cancer with a relative risk of 60.2 compared to a relative risk of 9.6 in those that are hepatitis 
B e antigen negative (Yang, 2002). Similar observations apply to those who have high 
hepatitis B DNA levels. In recent times, the improved antiviral therapies against hepatitis B, 
and the successful vaccination programs have helped lower the incidence of hepatocellular 
carcinoma particularly in what are considered endemic areas for hepatitis B (Chang et al., 
1997; Sung, 2008). 
The incidence of hepatitis C-related hepatocellular carcinoma has not seen the same 
encouraging trend that is been observed in hepatitis B-related cases. This is probably due to 
the interplay of numerous factors that include the natural history of the hepatitis C virus 
infection, host responses, age at the time of infection, co-morbidities, and alcohol 
consumption, to name a few. Approximately 15 to 20% of the chronic hepatitis C-infected 
individuals will develop cirrhosis over a period of 25 to 30 years from the time of infection 
(Thein, 2008). In developed countries such as the United States, the majority of the infections 
occurred from the late 1960s to the 1980s, thus in part explaining the rising number of 
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persons that are being diagnosed with hepatitis C-related cirrhosis over the last couple of 
decades (Davis, 2010). Hepatocellular carcinoma develops in this population at a rate of 1 to 
4% per year, a worrisome statistic considering the escalating numbers of persons diagnosed 
with hepatitis C-related cirrhosis.  
2.3.2 Alcohol 
Alcohol consumption has also been linked to primary liver cancer. Mechanisms for direct 
toxic or carcinogenic effect have not been well-recognized, but it is clear that extended 
periods of heavy ingestion of more than 60g per day increment the risk for hepatoma. The 
synergistic effects of alcohol in the presence of hepatitis B or C or both have been 
established, and seem to have a greater impact in the risk to develop hepatocellular 
carcinoma (Donato et al., 2002). 
2.3.3 Aflatoxin 
A connection between the environmental exposure to aflatoxin, a mycotoxin produced by 
Aspergillus fungus, and primary liver cancer has also been documented. The chronic dietary 
exposure to high levels of this toxin is seen predominantly in developing countries, where 
hepatitis B is also prevalent. It has been postulated that the overall contribution of aflatoxin 
exposure to hepatocellular carcinoma cases worldwide is between 5 and 28% (Y. Liu 2010). 
However, taking into account that hepatitis B infection seems to play a much greater role in 
the risk of development of hepatoma in these developing countries, the true contribution of 
aflatoxins is considered minimal. It appears that the mechanism by which this toxin has 
carcinogenic effects is by causing mutations in the p53 tumor suppressor gene (Gursoy-
Yuzugullu, 2011). 
2.3.4 Nonalcoholic fatty liver disease 
Nonalcoholic fatty liver disease is the most common form of chronic liver disease in 
developed countries. When aggressive, this disease can progress to cirrhosis and 
hepatocellular carcinoma. The alarming obesity epidemic affecting many of these nations, 
and components of the metabolic syndrome in particular insulin resistance and diabetes, are 
factors associated with the development of this chronic disease. These factors by themselves 
have also been related to an increased risk of primary liver cancer (Calle, 2003; El-Serag, 
2004). Considering our current understanding of its rising prevalence, nonalcoholic fatty 
liver disease could also be responsible for a significant number of the idiopathic or 
cryptogenic cirrhosis cases as well as the cryptogenic cirrhosis-related hepatoma cases that 
are seen in industrialized countries (Bungianesi, 2002). Recent studies have shed some light 
of the molecular mechanisms by which fatty liver and obesity could eventually lead to 
hepatic cancer (Beyazit, 2010; Park et al., 2010; Wree, 2011). 
3. Staging systems for HCC 
One of the most fundamental steps in the field of Oncology once the diagnosis of cancer has 
been established is to determine the stage of this malignant process. This step is very 
important as it provides information about overall survival and prognosis, and could help 
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guide treatment strategies. The ideal staging system for hepatocellular carcinoma is one that 
has high discriminatory ability while remaining simple (Dohmen, 2004).  
Many staging systems for hepatoma have been developed and presented in reputable 
medical journals and conferences. Nonetheless, more studies are constantly being published 
comparing these models, showing results of modifications made to some of these systems or 
simply introducing new staging classifications into this already complex field that tries to 
find the most accurate measure of prognosis and survival. The difficulty of coming up with 
a globally accepted staging system is related to multiple factors. One of the main causes for 
the current discrepancies is that the risk factors and their contribution to the development of 
primary liver cancer vary from one geographic area to another (Marrero, 2010). Another key 
issue is that overall survival of individuals that are diagnosed with hepatocellular 
carcinoma is not only determined by the extent and characteristics of this malignancy, but 
also by the liver function of that individual. Considering that over 80% of the cases of 
hepatoma occur in the presence of chronic liver disease and cirrhosis, the role of liver 
function in a prognosis model cannot be ignored. However, there is disagreement as to 
which markers of liver function should be used or included in such models. The use of the 
available staging classifications differ from one center or institution to another. It depends 
on their experience, available resources, and the predominant manifestations and 
characteristics of hepatocellular carcinoma in their region. Some of the main and most 
studied staging systems will be described below. 
3.1 Tumor-node metastasis (TNM) system 
The tumor-node-metastasis (TNM) staging system is one of the earliest models developed, 
and has been widely used for different solid tumors. This system describes the anatomic 
extent of cancer by evaluating size of the tumor at the primary site as well as the presence or 
absence of tumor in regional lymph nodes or beyond (Greene & Sobin, 2008). This 
classification has been studied in populations with hepatocellular carcinoma to assess 
prognosis. In a recent Chinese study looking at 243 patients with hepatoma undergoing 
curative resection, TNM classification was better at prognostic stratification and prognostic 
prediction than other three models (Lu, 2008). Similar conclusions were drawn from another 
smaller study comparing the prognostic value of TNM to 6 other staging systems (S.B. Choi, 
2008). However, additional studies have shown no superiority to other staging 
classifications (Chen, 2007). There are some drawbacks to the use of this system in primary 
liver cancer. The main flaw is that liver function is not taken into consideration in this 
prognostic model. Another problem is that grading and pathologic staging cannot be 
assessed in the majority of the cases because very few patients with hepatoma undergo 
surgical therapies (Dohmen, 2004). 
3.2 Cancer of the Liver Italian Program (CLIP) 
The CLIP scoring system is another option available to evaluate overall survival in patients 
with hepatocellular carcinoma. This model combines Child-Pugh score, tumor morphology, 
alpha feto-protein (AFP) and portal vein thrombosis which were the four independent 
predictive factors of survival recognized in the multivariate analysis of the original 
retrospective study (Cancer of the Liver Italian Program [CLIP] Investigators, 1998). By 
tumor morphology the investigators meant percentage of parenchymal involvement (more 
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than or less than 50%) and if these were uninodular, multinodular or extensive tumors. 
Several subsequent studies with large patient populations have demonstrated its prognostic 
usefulness, including a recent study from Taiwan that compared this system to four other 
models in 1713 patients with primary liver cancer (Hsu, 2010; Ueno, 2001). A downside to 
this system is that its tumor morphology classification is too broad for the current practices 
of aggressive hepatoma screening in high risk populations. Nowadays, more patients are 
being diagnosed with very small tumors which could limit the use the CLIP score. This 
model has also been criticized for not discriminating well the cases of advanced stage (CLIP 
score 4-6), and for classifying most of the patients as early stage (CLIP 0-2), which hampers 
its stratification capacity (Dohmen 2004; Marrero et al., 2010). 
3.3 Japanese Integrated Staging (JIS) and biomarker-combined JIS 
In an attempt to also combine liver function and tumor characteristics in order to provide a 
more precise prognostic appraisal to patients with hepatocellular carcinoma, researchers in 
Osaka, Japan integrated the Child-Pugh score and the Japanese TNM staging to create the 
JIS system. In their evaluation of 722 cases with primary liver cancer, they concluded that 
compared to the CLIP score, their system was better stratifying patients and superior 
discriminating those cases that were in the early hepatoma phase. Statistically significant 
differences were seen for the lower JIS scores (Kudo et al., 2003). These findings suggest that 
this staging system could be more useful in regions where early detection of hepatocellular 
carcinoma has become more common. Other studies have found encouraging results of this 
model’s ability to predict survival (Chen, 2007; Kudo, 2004; Nanashima, 2005). The main 
disadvantage of the JIS classification is the inability to discriminate well the cases of 
advanced stage (JIS score >4). 
Biomarkers have been combined to the JIS system to determine if this modification enhances 
its prognostic value. The biomarker-combined JIS includes the assessment of the following 
three tumor markers for hepatoma: AFP, lens culinaris agglutinin-reactive AFP, and des-
gamma-carboxyprothrombin. This modified system was studied in 1,924 patients with 
primary liver cancer, and proved to be more effective predicting prognosis and stratifying 
patients than the conventional JIS model (Kitai, 2008). Although this was a large provocative 
study, this combined system needs to be tested in populations outside of the Asian region. 
3.4 Barcelona Clinic Liver Cancer (BCLC) staging system 
The Barcelona Clinic Liver Cancer staging system has one peculiarity that is not present in 
any of the other available prognosis models: it incorporates treatment recommendations in 
its staging algorithm. The independent predictors of mortality in the original studies were 
constitutional syndrome, performance status, vascular invasion, and extrahepatic spread 
(Llovet, 1999a, Llovet, 1999b). By combining in a simple format the evaluation of liver 
function, tumor stage, performance status, and cancer-related symptoms, and providing 
suggestions to the best available therapeutic modalities for any particular stage, the BCLC 
system has demonstrated better predictive value of prognosis and survival stratification 
when compared to several other staging systems (Cillo, 2004; Guglielmi, 2008). This 
classification has been gaining wide acceptance as the main staging model used in multiple 
countries, and supported by several well-respected liver societies. This is related in part to 
the fact that the BCLC has been externally validated in Asia, Europe and the United States 
www.intechopen.com
 
Liver Transplantation for Hepatocellular Carcinoma (HCC) 
 
283 
(Cillo, 2006; Marrero, 2005; J.H. Wang, 2008; Xu, 2010), which has not been accomplished by 
many of the other staging models. It is also the principal system used in major drug 
company trials. Some of the criticism to this model is that it includes the subjective factor of 
performance status, and portal hypertension measurement, which in clinical practice is not 
routinely done. It also does not provide a classification for patients with single tumors 
greater than 5 centimeters in diameter or for those with recurrent disease after treatment, 
situations not infrequently encountered by clinicians treating hepatocellular carcinoma 
(Sherman, 2011).  
There are many other classifications that have been developed to evaluate overall survival 
and prognosis. Some of these include the Okuda classification, the Chinese University 
Prognostic Index, the Advanced Liver Cancer Prognostic system, the Groupe d’Etude et de 
Traitement du Carcinome Hepatocellulaire score, to name a few. Initial studies for several of 
these models have shown some prognostic value, but they all need further validation in 
larger more diverse populations.  
4. Workup of the patient with diagnosis of HCC 
4.1 Imaging studies 
The key radiographic feature of hepatocellular carcinoma is the presence of arterial 
enhancement and venous washout in contrast enhanced imaging studies (Bruix & Sherman, 
2010). The clinical staging of this cancer requires radiologic tests that would provide the 
finest of details about its gross morphology and extent of involvement. This information will 
be crucial to direct therapeutic decisions and to provide a better estimate of prognosis to the 
patient.  
Liver transplantation is one of the curative treatment options for early stage hepatocellular 
carcinomas that meet specific criteria. Careful assessment with imaging studies helps select 
the most suitable candidates for this treatment option. Particular attention is paid to tumor 
size, the number of lesions, any presence of vascular invasion, as well as evidence of distant 
metastasis. The most common sites of extrahepatic metastasis are the lungs, abdominal 
lymph nodes and bones (Katyal, 2000). 
Groundbreaking technological advances in computer tomography (CT), magnetic resonance 
(MR), ultrasonography, and other imaging modalities have been studied to determine their 
significance in the workup patients with primary liver cancer. Ultrasound has its merit in 
screening for hepatomas as it is noninvasive, offers no radiation exposure, is readily 
available in most centers, and is inexpensive compared to other imaging techniques. 
Unfortunately its sensitivity is not satisfactory in cirrhotic patients, and lesions can be 
missed (Kim, 2011). Nonetheless, the corner stones and only accepted techniques for staging 
hepatocellular carcinoma before liver transplantation are contrast-enhanced CT or MR (J.M. 
Lee, 2011). 
4.1.1 Computer tomography (CT) 
Computed tomography has proven to be a great tool for the evaluation of hepatocellular 
carcinoma in affected patients. It is also commonly the test of choice when looking for 
extrahepatic metastatic disease. The improvements in the scanners, their resolution as well 
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as the intravenous contrast material used in these studies, has improved the detection of this 
hepatic malignancy (B.I. Choi, 2010). The use of multidetector CT scans, for example has 
markedly highlighted the hypervascular characteristics of hepatomas which were not as 
evident in earlier CT scan technology (K.H. Lee, 2004). The sensitivity of CT scans has 
increased due to these advances. However, some studies have shown that the improved 
accuracy of this imaging technique is more apparent in the detection of larger tumors with 
classic radiographic features, and when the studies are interpreted by more experienced 
radiologists (Addley, 2011). It seems that in the setting of cirrhosis and when the lesions are 
smaller than 1 centimeter in diameter, CT has difficulties over and underestimating the 
diagnosis of hepatocellular carcinoma (Luca, 2010; Ronzoni, 2007). Similar observations 
have been shown in large and experienced liver transplant centers were the false positive 
diagnosis rate of primary liver cancer has been reported as high as 8%, and predominantly 
seen in lesions that were between 0.75 and 1.5 centimeters in diameter (Brancatelli, 2003). 
Perhaps the continued progress in the field of computed tomography might some day better 
characterize these small lesions. 
4.1.2 Magnetic resonance (MR) 
Magnetic resonance imaging provides another suitable option in the staging of 
hepatocellular carcinoma during the liver transplantation workup. There is ample evidence 
that attests the important role of MR in the diagnosis and description of hepatomas. The 
development of faster MR techniques has contributed to obtaining multiphase intravenous 
contrast-enhanced images that capture with more detail the hypervascular characteristics of 
this cancer. One of its most important attributes is its superior ability for the detection of 
small liver tumors, particularly those less than 2 centimeters in diameter (Burrel, 2003; Colli, 
2006; Golfieri,2009, D.H. Lee, 2009,). Given the reported higher sensitivities and accuracy 
detecting these malignant lesions with the newer MR techniques and contrast agents, many 
transplant centers have adopted MR as their study of choice when evaluating potential 
transplant recipients with cirrhosis. One cannot forget that as in the case of CT scans and 
other imaging modalities, the detection and characterization of hepatocellular carcinoma 
could also be in part influenced by the experience of the radiologists interpreting these 
studies. MR use is limited in the setting of patients that have certain types of metallic 
medical implants or other devices, and on those who are claustrophobic or cannot hold their 
breath. Recently, gadolinium contrast has also been linked to nephrogenic systemic sclerosis 
which also limits the use contrast-enhanced MR in patients with significant renal failure, a 
not uncommon situation in the cirrhotic patient population (Idee, 2009). Nonetheless, the 
current available evidence has MR as the clear frontrunner in the search for the best imaging 
modality for diagnosing and characterizing hepatocellular carcinoma. 
4.1.3 Contrast enhanced ultrasound (CEUS)  
Contrast-enhanced ultrasonography’s (CEUS) capability of detecting vascular liver lesions, 
particularly hepatomas, has been studied and shown some promise (Forner, 2008; Jang, 
2007). This modality has even demonstrated remarkable sensitivities and accuracy of 87 and 
93% respectively, for diagnosing liver cancer in lesions less than 2 centimeters in diameter 
(Jang, 2009). Other studies have looked at its utility characterizing portal vein thrombosis as 
malignant or benign. This differentiation is critical as it has major implications for those 
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patients being evaluated for liver transplantation. When compared to spiral CT for the 
detection and characterization of portal vein thrombosis in 50 patients with hepatocellular 
carcinoma and biopsy-proven portal vein thrombosis, CEUS outperformed CT by detecting 
100% of the thrombi and correctly characterizing 49/50 (98%) of them. CT modality detected 
and correctly characterized 68% of these portal vein thrombi, respectively (Rossi, 2008). 
CEUS has also demonstrated to be as valuable when compared to biopsy for the assessment 
of the benign or malignant nature of these thrombi (Sorrentino, 2009). Major drawbacks of 
this modality are that CEUS is still not available in many countries, and that it is operator 
dependent. 
4.1.4 Other imaging studies 
Extrahepatic metastasis is not common in early stage hepatocellular carcinoma (Si, 2003). 
Nevertheless, physicians working at transplant centers fear to miss its presence in a liver 
cancer patient who is potentially going to be listed for liver transplantation. The United 
Network for Organ Sharing (UNOS) implemented a policy in which all centers need to 
include a chest CT to their protocol to evaluate for lung and lymph node metastasis of 
hepatoma patients being considered for transplantation (United Network for Organ Sharing 
[UNOS], 2010). Bone is the other preferred site of spread, and although UNOS had included 
bones scans in the policies implemented in the 1990s, in light recent evidence provided by 
several studies, this decision was amended in their most recent liver allocation statements. 
The significant number of false positive or indeterminate results obtained with this modality 
is a major disadvantage, as well as the costs incurred for a study that has little impact in the 
selection of patients given its negligible true-positive yield (Koneru, 2005; Sheth, 2005). 
The role of positron emission tomography (PET) has also been studied in patients with 
hepatocellular carcinoma. In general, the sensitivity of this modality for detection of 
hepatoma that is less than 5 centimeters in diameter has been low (Trojan, 1999; Wolfort, 
2010). PET may have some utility identifying extrahepatic metastasis, but the data available 
is not strong and sufficient enough to widely recommend this practice (Yoon et al., 2007). 
4.2 Biopsy 
The use of liver biopsies in the setting of hepatocellular carcinoma is controversial. The 
radiological advances that have taken place over the past decade have markedly improved 
detection and characterization of this malignancy, thus reducing the need for liver biopsies 
to confirm the diagnosis. The United Network for Organ Sharing has stated in its liver 
allocation policy that biopsy is not mandatory in cirrhotic liver transplant candidates with 
hepatoma as long as the lesion meets imaging criteria (UNOS, 2010). As a result, liver 
biopsies are now reserved to situations in which the lesion’s radiographic studies are not 
showing the typical features of enhancement in arterial phase and washout in portal venous 
phase. This rule applies to tumors greater than 2 centimeters in diameter lacking classic 
features in one imaging modality, and to lesions between 1 and 2 centimeters in diameter 
with atypical radiographic characteristics in two different imaging modalities (Bruix & 
Sherman, 2010). 
Pathologic staging of hepatocellular carcinoma is established the majority of the time after 
surgery (resection or transplantation), whereas clinical staging predominantly relies on 
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imaging studies and is done before the treatment is decided. Some groups advocate 
obtaining a pretransplant liver biopsy to exclude candidates with poorly differentiated 
tumors and to identify patients that might need more aggressive bridging therapy. Dubay 
and colleagues evaluated this and found that in patients exceeding Milan criteria (single 
tumor not greater than 5 centimeters in diameter or up to 3 tumors none larger than 3 
centimeters in diameter) there was a significant increase in overall 5-year survival (61% 
versus 79%, p=0.03) after the introduction of pretransplant liver biopsies and the use of 
aggressive bridging therapies (Dubay, 2011). The authors of this study conclude that tumor 
differentiation might be a more important predictor of biologic behavior than other factors 
such as size, total tumor diameter, multifocality, and microvascular invasion.  
Performing liver biopsies in any patient population carries risks that although small, are not 
negligible. While pain is the most common complication, bleeding is the most feared and 
important complication. Severe bleeding events requiring hospitalization and other 
interventions occur anywhere from 1 in 2,500 to 1 in 10,000 in patients with diffuse, nonfocal 
liver disease (Rockey, 2009). However, the bleeding risk may be higher in cirrhotic patients, 
who usually have some degree of coagulopathy and thrombocytopenia. Similar increased 
risk could be expected in cirrhotic individuals in whom a highly vascular lesion such as 
hepatocellular carcinoma is being percutaneously biopsied (Huang, 1996). Tumor seeding 
along the needle track after biopsy has also been reported as a complication in this 
population (Dubay, 2011; Huang, 1996; Schotman, 1999; Sood, 2002). A recent systematic 
review and meta-analysis showed that the overall incidence of needle track tumor seeding is 
2.7%, or 0.9% per year (M.A. Silva, 2008). These statistics are probably not too high because 
biopsy of primary hepatic cancer is not a common practice nowadays. However, the risks 
and benefits of biopsying a liver lesion must always be carefully weighed. This procedure 
should be reserved to instances when there is reasonable doubt about the diagnosis of 
hepatoma.  
4.3 Criteria for liver transplantation 
The field of liver transplantation has gone through many transformations since its early 
days. Over time this surgical procedure evolved from being a treatment option mostly for 
individuals with irreversible severe liver dysfunction from any acute or chronic illness to 
also a providing a proven curative alternative for patients with early stage hepatocellular 
carcinoma. Currently, the success rate and outcomes seen in this subset of liver transplant 
recipients is similar to that of recipients who underwent transplantation for indications 
other than hepatoma. This is in great part due to the knowledge and understanding obtained 
from outstanding clinical studies published over the last 20 years (Bismuth, 1993; Figueras, 
1997; Iwatsuki, 1991; Mazzaferro, 1996; Tan, 1995). These studies have paved the way to the 
creation of the criteria for liver transplantation and guidelines that are used today. 
4.3.1 Milan criteria 
The Milan criteria are at the present time the accepted and recommended measure to 
determine the liver transplantation candidacy of patients with hepatocellular carcinoma. 
This criteria described in a landmark paper by Mazzaferro and colleagues, demonstrated 
that in patients with cirrhosis and a single tumor up to 5 centimeters, or up to three lesions 
none larger than 3 centimeters, and with no evidence of extrahepatic spread or 
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macrovascular invasion the 4-year post-transplant survival was similar to that of recipients 
transplanted for reasons other than liver cancer (Mazzaferro, 1996). These findings of greater 
than 70% survival rate gave a second chance to the previously aborted efforts of 
transplanting cirrhotic patients with primary liver cancer. The United Network for Organ 
Sharing endorses these criteria, and adopted them for their liver allocation policies of 
patients with hepatocellular carcinoma (UNOS, 2010). Despite being validated by many 
studies, some believe that the Milan criteria are too restrictive and exclude a subset of 
patients with hepatoma that could have excellent outcomes if were transplanted (M.F. Silva 
& Sherman, 2011).  
4.3.2 University of California, San Francisco (UCSF) criteria 
Several groups have carried out studies in an effort to determine if patients with 
hepatocellular carcinoma exceeding Milan criteria could have similar survival and 
recurrence-free rates than those within the criteria. Yao and his colleagues from the 
University of California, San Francisco (UCSF) were the first to challenge the parameters set 
by the Milan criteria. In their retrospective study, cirrhotic patients with a single tumor up 
to 6.5 centimeters, or up to three lesions none larger than 4.5 centimeters, and total tumor 
diameter of no more than 8 centimeters had a 1-year and 5-year overall survival of 90% and 
75.2%, respectively (Yao, 2001). The UCSF criteria were validated by the same group when 
they prospectively demonstrated comparable recurrence-free survival between the patients 
meeting Milan criteria and those meeting UCSF criteria (Yao, 2007). Unfortunately, data 
about overall 5-year survival was not included in that study.  
4.3.3 Other criteria 
Following the thought provoking findings of UCSF’s study, other groups have also 
ventured into pushing the limits set by the Milan criteria without compromising overall 
patient survival and hepatoma recurrence rate. However, several shortcomings affect the 
validity of these studies. Most of them are retrospective studies, many do not clearly define 
the size of the tumors, in particular the upper limits, and others have small number of 
patients to provide convincing and significant findings. In contrast, the results of a recent 
well-designed, prospective, multi-center study from UNOS region 4 support the belief that 
liver transplantation could benefit patients whose hepatocellular carcinoma exceed Milan 
criteria. UNOS region 4 criteria showed patient, allograft and recurrence-free survival to be 
similar between patients meeting Milan criteria and those meeting their suggested criteria 
which consists of one lesion up to 6 centimeters, up to three nodules none larger than 5 
centimeters, and a total tumor diameter less than 9 centimeters. It will be interesting to see if 
the data from their 5-year follow up still shows comparable survival rates (Guiteau, 2010). In 
general, the encouraging results seen from many of the extended criteria studies have 
stimulated the discussion about amending the current selection criteria to include this 
subgroup of liver cancer patients that could also benefit from transplantation. 
5. Bridging therapies 
Due to the aggressive nature of HCC, liver transplantation is of paramount importance in 
the eradication of HCC and cirrhosis, as it results in a 5-year overall survival of 70% and a 
recurrence rate of less than 15% among patients whose HCC falls within established criteria  
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(Decans, 2005; Wigg, 2010). However, fewer than 25% of all patients with HCC qualify for 
liver transplants. Due to an organ shortage, the average wait period for a liver transplant is 
6-9 months. Increased waiting time for HCC patients increases the risk for tumor 
progression, even with priority listing, and waiting list drop-out, which is defined as 
withdrawal from the transplant waiting list due to death; tumor progression; or reasons 
such as becoming too ill for transplantation (Majno, 2010). The dropout rate for HCC 
patients on the waiting list is 8.7%, 16.9%, and 31.8% at 90, 180, and 365 days respectively. 
As the doubling time for HCC is approximately 6 months without treatment (Lee, 2007), 
increased waiting time for transplantation is problematic, and Model for End-Stage Liver 
Disease (MELD) exception points have been implemented to combat this issue. Since the 
institution of the MELD system in 2002, transplant candidates with HCC are applicable for 
listing prioritization via MELD exception points. Patients with HCC within Milan criteria 
(MC) and in some regions, San Francisco criteria, are granted a MELD exception of 22, 
followed by upgrades to 25 and 28 every 3 months provided that their tumor burden 
remains within range. MC is defined as 1 lesion ≤ 5 cm or up to 3 lesions ≤ 3 cm. Exception 
points result in shorter time to transplant – in 2007, approximately 62% of patients 
nationwide underwent transplantation within 3 months of receiving exception points for 
HCC (Yao, 2008). However, this system can be controversial, as some believe that tumors do 
not adequately degenerate between the time of ablative therapy and transplantation and 
that it is safer to wait 6 months after bridging before the patient is transplanted (Roberts, 
2010). Others argue that tumor size limits are excessively exclusive and that Milan criteria 
should be expanded to include a larger tumor burden (Yao, 2008). While patients wait for 
transplant, loco regional ablative therapy, or bridging therapy, in the form of modalites such 
as Transarterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) is often 
employed with the goals of decreasing the waiting list dropout rate; decreasing the rate of 
tumor recurrence post transplant; and increasing long term survival after transplant (Lee, 
2007). The BCLC staging and treatment strategy incorporates the different ablative therapies 
in patients with early stage (0); early stage (A); and intermittent stage (B) HCC.  
5.1 Goal of ablative therapies 
Bridging therapy for HCC serves the following roles: 1) to downstage HCC in patients 
whose tumor burden is outside MC to make the patient transplantable; 2) to prevent disease 
progression in patients within MC as they await transplant; and 3) to provide palliative and 
curative therapy in patients who are not OLTx candidates (Table 1). Bridging therapy can 
also improve the results of transplantation by excluding patients with recurrent disease or 
unfavorable tumor biology (Majno, 2010). An example of an integral management of HCC is 
shown in Graph 1. 
Downstaging to Milan/ UCSF criteria 
Prevent disease progression on the wait list 
Prevent dissemination during liver manipulation at transplant surgery 
Tumor therapy in non transplant/ non surgical candidates 
Palliative therapy 
Table 1. Goal of bridging therapies 
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Multifocal HCC Unifocal HCC
Child’s AChild’s B - C
Loco regional therapies
(RFA/Radiospheres/Chemoembolization)
+/- Sorafenib 
Restage at 3 month intervals
Meets Region 4 criteria and transplant candidate
YES
List for OLT
NO
Laparoscopic or open 
resection
 
Graph 1. HCC Management algorithm at The Liver Institute at Methodist Dallas 
5.2 Transarterial chemoembolization (TACE) 
Of all bridging therapies, TACE is the most validated and widely studied. TACE consists of 
occluding blood supply to the tumor or tumors and delivering a chemotherapy agent to the 
tumor via a branch of the hepatic artery which specifically supplies the tumor. During 
TACE, a chemotherapy agent such as doxorubicin or cisplatin in combination with lipiodol 
is injected, followed by an agent such as Gelfoam to occlude the tract. An advantage of 
TACE is that its use results in a high concentration of chemotherapy to the tumor or tumors; 
also it is useful in downstaging tumors larger than 3 cm (Pompili, 2005). A disadvantage of 
TACE is that it is less tolerated among patients with severe hepatic decompensation, such as 
in patients with ascites and impaired coagulopathy. Also, it is contraindicated in patients 
with portal vein thrombosis. A meta-analysis of several studies showed a median survival of 
20 months with arterial embolization. In one study of 61 patients, the survival rate among 
those who received TACE at 1 and 4 years post transplant was 87.5% and 69.3%, 
respectively (Yao, 2008).  
5.3 Radiation ablation (RFA)  
In RFA, a radiofrequency (RF) probe containing an alternating current of approximately 500 
kHz and 131 degrees Fahrenheit, is inserted in or around a hepatic tumor via ultrasound 
guidance for approximately 4-6 minutes (Yao, 2008). Its mechanism of action is inducing 
thermal energy to the tissue via electromagnetic energy (Lee, 2007). Many centers use 
microwave ablation in contrast to RFA with similar or better results.In a study of 40 patients 
who underwent RFA, the rate of complete necrosis was 51.3% for nodules smaller than 3 cm 
and 14.3% for larger lesions (Pompili, 2005). In accordance with this study, TACE is 
perceived as more effective than RFA in treating lesions larger than 3 cm. The limitations of 
RFA are the anatomical location of the tumor, presence of large ascites, and multifocal HCC, 
in which cases it cannot be used. 
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5.4 Percutaneous Ethanol Injection (PEI) 
In Percutaneous Ethanol Injection (PEI), ultrasound guidance is used to deliver ethanol over 
4-8 sessions performed 1-2 times per week. Its mechanism of action is inducing local tumor 
necrosis as a result of cellular dehydration, protein denaturalization, and chemical occlusion 
of tumor vessels (Pompili, 2005). PEI is most effective in treating nodules <3 cm and is 
overall better tolerated than TACE. However, its major limitation is a high local recurrence 
rate, which can reach up to 43%. Other limitations include a long treatment time. Overall, 
RFA has better outcomes than PEI and is better tolerated. In one study, the overall 1-2 year 
survival rates were higher among patients treated with RFA versus PEI were 86% and 64% 
versus 77% and 43% respectively (Lencioni, 2010). PEI has similar limitations but less 
efficacy than RFA and is infrequently used in North America for treatment of HCC. 
5.5 Yttrium microspheres  
Treatment with Yttrium glass microspheres occurs when a catheter is placed in the hepatic 
artery and the Therasphere vial, which is comprised of silica containing Yttrium, is 
rapidly injected. The intent is to deliver 125–150 Gy (12,500 –15,000 rads) of radiation to the 
tumor or tumors. In a study of 65 patients treated from August 2000 to August 2003, 42 
patients (64.6 %) had a significant decrease in tumor size within 4 months. The median 
survival among Okuda stage I patients was 649 days in historical comparison to a median of 
244 days. The median survival among Okuda stage II patients was 302 days in historical 
comparison to a median of 64 days (Carr, 2004). A benefit of this procedure is that it is 
generally better tolerated than TACE. Drawbacks are potential radiation to other organ 
systems and elevated cost. Also, it is also contraindicated in patients with severe liver 
synthetic dysfunction. To be eligible for treatment, a patient must be relatively well-
compensated, with a bilirubin < 2.0 mg/dL, creatinine < 2.0 mg/dL, platelets > 60 K/L, a 
lung shunt < 16%, and ECOG performance < 2 (Carr, 2004). 
5.6 External Beam Radiation Therapy 
External Beam Radiation Therapy (EBRT) occurs when radiation is delivered to a tumor 
after the placement of fiducial markers, which are markers are implanted via sterilized 
needles under ultrasound or CT guidance. Some clinical reports have demonstrated 
response rates to EBRT ranging from 80-87.5 for small HCC. EBRT may achieve a 10-12 log 
decrease in tumor, compared to up to 6 logs associated with chemotherapy. An advantage is 
that EBRT can be delivered to multiple lesions regardless of the proximity of the tumor or 
tumors to major hepatic vessels or bile ducts. Another advantage is that it is less costly than 
procedures such as treatment with Yttrium glass Microspheres: an estimation of EBRT is 
$4,047 for treatment and consultation (Wigg, 2010).  
6. Surgical therapies for HCC 
6.1 Surgical resection for Hepatocellular carcinoma 
Surgical resection is contraindicated in patients with decompensated liver disease or Child’s 
B-C classifications. In patients with Child’s A cirrhosis and lack of portal hypertension, 
resection can be offered as an alternative to transplantation. The advantages of resectional 
therapy over liver transplantation include: no waiting time, no need for long-term 
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immunosuppression, can be offered to older patients, cost and transplant can be reserved as 
a salvage therapy. However, liver transplantation can cure not only HCC but also cures the 
cirrhosis in the remnant liver. Therefore, cancer recurrence in the remnant liver is a 
significant disadvantage for the resected patients. Poor prognostic factors identified after 
liver resection for HCC are microvascular invasion, positive margins and older age groups 
(>65 years old).When resection was offered to patients within Milan criteria, patients with 
solitary tumors (5 cm or less) had a significantly better 5-year survival rate of 70% versus 
46% in patients with 2-3 tumors less than 3 cm (Fan, 2011).In a meta-analysis of the medline 
database, the 1, 3 and 5 year survivals for liver resection of HCC were 80%, 55% and 37%, 
respectively. In the same study, liver transplantation for HCC carried a 1, 3 and 5 year 
survivals of 80%, 70% and 62%,respectively (Morris-Stiff, 2009).  
6.2 Salvage liver transplantation after liver resection 
The use of resection as a bridge to transplantation has been advocated as a way of solving 
the organ donor shortage, whereby transplantation is offered only to patients who develop 
an intrahepatic recurrence. In the United States, a national Consensus Conference on Liver 
Allocation for HCC, recommended that : 1- a recurrence more than 2 years after resection for 
HCC of any stage should be considered de novo, and to considered priority score for HCC if 
the lesion meets Milan criteria; and 2- a recurrence that presents less than 2 years after 
resection for a T2 lesion should be elegible for HCC priority score if the lesion meets Milan 
criteria (Pomfret, 2009). The largest series of salvage transplantation come from French 
centers with conflicting results: Adam et al (Adam, 2003) report a 5 year survival for salvage 
transplantation of 29% versus 58% for primary liver transplantation for HCC. In their series, 
the recurrence rate for liver resection was 77% but only 17% of patients were elegible for 
salvage transplantation.By utilizing a strategy that offers salvage transplantation for 
decompensated liver function and positive margins after resection, Belghiti et al ( Belghiti, 
2003) have shown a comparable 5 year survival for both salvage and primary liver 
transplantation of 59% and 61%, respectively. The use of resection as a bridge to 
transplantation may offer important histopathological information that can help identify 
and subselect patients best suited for transplantation but its application is limited by the fact 
that only a relatively small number of patients with hepatocellular cancer are candidates for 
liver resection. 
6.3 Laparoscopic resection for HCC 
In cirrhotics with preserved liver function and the absence of significant portal 
hypertension, the laparoscopic approach carries several benefits. Due to the smaller 
incisions, the collateral abdominal wall circulation is better preserved and an increase in the 
portal pressure is avoided. Intra-abdominal adhesions are decreased and successful salvage 
transplantation after laparoscopic resections have been reported (Laurent, 2009). The 
accepted criteria for laparoscopic approach include: single lesions in peripheral segments of 
the liver and less than 6 cm in size (Buell, 2008).Outcomes after laparoscopic resection for 
HCC range from 68 to 74 % 3-year survival (Chen, 2008).In Europe, the 1 and 3 year disease-
free survival after laparoscopic resection is 77.5% and 47.1%, respectively (Dagher, 2010); 
Pittsburgh reported an 88% and 82% disease-free survival at 1 and 3 years, respectively 
(Nguyen,2011). The option of laparoscopic or open liver resection for HCC should be 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
292 
considered in the context of a multidisciplinary approach to the individual patient’s tumor, 
liver reserve and potential transplant candidacy. 
7. Liver transplantation for HCC 
7.1 Technical considerations of liver transplantation for HCC 
Patients undergoing liver transplantation for HCC do not usually have the same degree of 
liver dysfunction than their counterparts. This difference can be explained for example by 
the use of allocations systems such as the UNOS (United Network for Organ Sharing), 
where patients with HCC are prioritized based upon tumor criteria rather than the MELD 
score. As a result, patients undergoing liver transplantation for HCC can have a lesser 
degree of portal hypertension and the hepatectomy phase of the operation is usually less 
demanding (Table 2). For this reason, cell savers are usually not needed and should be 
avoided in case any tumor cells are present in the blood. From the technical standpoint, a 
few aspects should be considered. Every patient should have a recent staging no older than 
3 months when brought in for the transplant. A thorough evaluation of the abdomen and 
hilum should be performed prior to dividing vital structures and if needed, lymph node 
biopsies should be obtained to rule out the possibility of metastatic disease. The patients 
should be informed of the possibility of incidental metastatic disease and no patient should 
be transplanted with known metastatic disease as this represents a contraindication. The 
possibility of a back up recipient should be considered in cases where patients are 
transplanted with criteria exceeding Milan or when the imaging is suggestive of possible 
metastatic or multifocal disease. Because the hepatectomy involves significant manipulation 
of the liver, pre-transplant tumor therapies are considered to be ‘preventive’ in releasing 
cancer cells in the circulation and are encouraged as a mean to prevent early recurrence of 
HCC. The survival benefit of pretransplant locoregional therapies has been demonstrated 
for trans-arterial chemoembolization (Maddala, 2004) and radiofrequency ablation (Pompili, 
2005).  
Recent Staging imaging (within 3 months) 
Back-up recipient available 
No cell saver 
Explore abdomen and hilar nodes before dividing vital structures 
No caval preservation if tumor close to cava 
Dissect artery carefully in cases with prior embolization procedures and be prepared for 
vascular grafts 
Table 2. Basic technical principles in Liver Transplantation for HCC 
Several techniques are available for the implantation of the liver: veno-veno bypass, standard 
technique with clamp and sew, piggy-back technique and caval preservation with or 
without temporary portocaval shunt. Different techniques have been compared but no 
study has proven superiority of any particular technique over the others (Sakai, 2010; 
Gurusamy, 2011; Viera de Melo, 2011). The caval preservation technique (piggy-back) is the 
preferred technique at many centers but should be avoided in cases where tumors are close 
to the retrohepatic inferior vena cava or adjacent to the hepatic vein-caval confluence.  
In cases where pre-transplant therapies have been performed such as chemo- or radio- 
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embolization, the gastroduodenal artery has usually been embolized and significant arterial 
inflammation and fragility can be encountered for the arterial anastomosis. For this reason, 
arterial grafts should always be available as an alternative mean for reconstruction. The 
portal vein should be inspected for the presence of thrombus and frozen sections of any 
large or suspicious clot should be obtained intraoperatively as tumor thrombus is an 
ominous finding that portends a poor prognosis and is a contraindication for 
transplantation. 
7.2 Immunosuppressive strategies after liver transplantation for HCC 
The optimal immunosuppressive regimen for post-transplant HCC patients remains a 
subject of debate and research. In the patients transplanted for HCC within Milan criteria 
and without high risk features on explants’ pathology, i.e. poor differentiation, vascular 
invasion or tumor viability, most centers would use the individual program’s routine 
regimen. There is data favoring the use of mammalian target of rapamycin inhibitors 
(mTORi) as part of the immunosuppression of any patient transplanted for HCC, however 
this is not widely accepted practice. In a large study based upon the Scientific Registry of 
Transplant Recipients, 2,491 patients transplanted for HCC were compared to 12,167 
patients transplanted for non-HCC diagnoses. In this study, a multivariate analysis 
demonstrated improved survivals for patients transplanted for HCC and induced with anti-
CD25 antibodies or maintained with a sirolimus-based regimen (Toso, 2010). A more 
challenging clinical scenario comes up when patients present with high risk tumor features, 
when the liver explants’ pathology reveals a larger tumor burden than anticipated and 
when the recipient presents with tumor recurrence. The use mTORi and sorafenib has been 
studied as a potential combination against Ras pathway activation in the genesis of 
hepatocellular carcinoma (Newell, 2009).The use of Everolimus or Sirolimus in combination 
with Sorafenib has anecdotally been proven to control HCC recurrence (Wang, 2010; 
Kim,2011). A close coordination between the transplant and oncology teams should be 
exercised in this scenario in order to avoid life threatening side effects of the 
immunosuppressive therapy chosen. 
8. Outcomes of liver transplantation for HCC  
The outcomes of Liver Transplantation for HCC have improved dramatically due to the 
introduction of tumor size criteria. In the 1990’s, inferior outcomes after transplant were 
experienced due to recurrence of HCC leading to patient death. An influential observation 
was made by the Milan group in 1996 and resulted in the Milan criteria (Mazzaferro, 
1996).This study showed that patients with pretransplant radiological evidence of 2 to 3 
tumors ≤ 3 cm in diameter or a single tumor ≤ 5 cm in diameter had a 4 year recurrence free 
survival of 92% when the explant confirmed the presence of these criteria. The United 
Network for Organ Sharing in the United States adopted the Milan criteria for 
transplantation and many publications have confirmed the validity of restricting the tumor 
size and number. Increasing the number and/or size of transplantable tumors has raised the 
concern of transplanting a higher incidence of tumors with microvascular invasion, 
microsatellitosis and poor differentiation (Table 3). In 2001, The UCSF reported outcomes for 
70 consecutive patients transplanted at their center and followed for 12 years (Yao et al, 
2001). They identified poor survival in patients with pT4 tumors, total tumor diameter ≥ 8  
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cm, age > 55 years, poorly differentiated histological grade and an - fetoprotein level > 1000 
ng/ml. The survival rates after liver transplantation of patients meeting the UCSF criteria 
(solitary tumor < 6.5 cm, or < 3 nodules with the largest lesion < 4.5 cm and total tumor 
diameter < 8 cm) on pretransplant imaging was 90% and 75.2%, at 1 and 5 years, 
respectively. There has been some criticism to the original Milan criteria due to its restrictive 
nature and for disallowing other potential candidates with HCC who may benefit from 
transplant. In addition to the UCSF report, another study has demonstrated reasonable 
outcomes after liver transplantation for HCC. The Metroticket Study group has described 
the Up-to Seven criteria: seven is the result of the sum of size (in cm) and number of tumors 
for any given HCC (Mazzaferro, 2009). This complex statistical analysis demonstrated that 
patients who fulfilled the up-to seven criteria but had no microvascular invasion, achieved 
overall 5-year survivals of 71%. At the present time, the expected survival of Liver 
Transplantation for HCC at 5 years is 70% and most current allocation systems work under 
this goal (which equals transplantation for non HCC indications). The future may bring less 
restrictive allocation rules, as long as the long term benefit is not inferior to the current 
standards and as long as patients awaiting transplantation for other indications are not 
disadvantaged. 
Macro and Microvascular invasion 
Poor differentiation 
Microsatellitosis 
- fetoprotein level > 1000 ng/ml 
Tumors exceeding standard criteria (Milan, UCSF, Up-to-seven) 
Table 3. Poor prognostic factors in Transplantation for HCC 
9. Future therapies and challenges 
Primary prevention and detection via sophisticated imaging studies, such as MRI and CT, 
are imperative for the elimination and minimization of HCC. Further research is also 
necessary in regards to bridging therapy. The development of molecular signatures which 
predict the natural behavior of HCCs is being explored, and this includes gene arrays which 
have already shown some promise. We can predict somewhat more accurately now than 
ever the propensity of tumors to metastasize and recur after transplant with certain markers 
such as micro vascular invasion or microsatellitosis on the explant speciments. The grade of 
HCCs, as characterized by an experienced pathologist on biopsy or explant, has gained 
importance over the years in prognosticating the natural history of the cancer and its risk of 
recurrence after resection or transplant. Immunohistochemical markers are being constantly 
developed- and some have already been tested– regarding the presence of positive CK7 and 
CK 17 staining in HCCs, which portends a more aggressive cancer with higher recurrence 
rates. The use of systemic chemotherapy in the form of multikinase inhibitors such as 
sorafenib in combination with ablative procedures such as TACE, RFA or radioembolization 
has been used with success and is likely to gain momentum in the future. Furthermore, 
systemic chemotherapy is more frequently employed after surgery or even after 
transplantation in patients with high risk tumors. An important consideration for bridging 
therapy is that it is difficult to completely eradicate tumors >3 cm in size or multifocal HCC, 
and this area especially merits further exploration. Finally, in the era of organ shortage, 
www.intechopen.com
 
Liver Transplantation for Hepatocellular Carcinoma (HCC) 
 
295 
alternative curative modalities to transplant are certainly a need of the hour. With advances 
in laparoscopic surgical techniques, use of portal vein embolization, and adequate and 
aggressive ablative techniques pre-operatively, more patients than in the previous years can 
be made suitable for surgical resection safely and effectively. On the vanguard of medicine 
is the phenomenon of stem cell research and a discussion on HCC is incomplete without its 
mention- like other solid tumors- it is believed though not completely elucidated that cancer 
stem cells may have an important role to play in the natural history and response to 
treatment of HCCs. Although these stem cells in the liver have not been accurately 
identified, there is intensive investigation in this area (Wen Xu, 2009). The further 
development of these stem cells has boundless potential in the prognostication and 
treatment of this cancer. 
10. References 
Adam R,Azoulay D, Castaing D et al. Liver resection as a bridge to transplantation for 
hepatocellular carcinoma on cirrhosis: a reasonable strategy ? Ann Surg 2003; 
238(4):508-518 
Addley HC, Griffin N, Shaw AS et al. Accuracy of hepatocellular carcinoma detection on 
multidetector CT in a transplant liver population with explants liver correlation. 
Clin Radiol 2011;66(4):349-56 
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, 
and survival trends in the United States from 1975 to 2005. J Clin Oncol 
2009;27(9):1485-91 
Belghiti J, Cortes A, Abdalla EK, et al. Resection prior to liver transplantation for 
hepatocellular carcinoma. Ann Surg 2003;238(6):885-892 
Beyazit Y, Kekilli M, Kurt M et al. Role of IL-6 activated STAT3 and TNF expression in 
obesity-associated hepatocellular carcinoma. Aliment Pharmacol Ther 2010;32:304-5 
Bismuth H, Chiche L, Adam R et al. Liver resection versus transplantation in cirrhotic 
patients with hepatocellular carcinoma in cirrhosis. Ann Surg 1993;218:145-51 
Bosch FX, Ribes J, Cleries R et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 
2005;9(2):191-211 
Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. 
Gastroenterology 2004;127(suppl 1):s5-16 
Brancatelli G, Baron RL, Peterson MS et al. Helical CT screening for hepatocellular 
carcinoma in patients with cirrhosis: frequency and causes of false-positive 
interpretation. Am J Roentgenol 2003;180(4):1007-14 
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. American 
Association for the Study of Liver Diseases, July 2010 
Buell JF, Cherqui D, Geller DA, et al. World Consensus Conference on Laparoscopic 
Surgery. The international position on laparoscopic liver surgery: the Louisville 
Statement, 2008. Ann Surg. 2009;250(5):825-830. 
Bungianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic 
steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. 
Gastroenterology 2002;123:134-40 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
296 
Burrel M, Llovet JM, Ayuso C et al. MRI angiography is superior to helical CT for detection 
of HCC prior to liver transplantation: an explants correlation. Hepatology 
2003;38(4):1034-42 
Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity and mortality from 
cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-
38 
Carr, B. Hepatic Arterial Yttrium Glass Microspheres (Therasphere) for Unresectable 
Hepatocellular Carcinoma: Interim Safety and Survival Data on 65 Patients. Liver 
Transplantation 10 (2004): 107-110.  
Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the 
incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma 
Study Group. N Engl J Med 1997;336(26):1855-9 
Chang MH, You SL, Chen CJ et al. Decreased incidence of hepatocellular carcinoma in 
hepatitis B vacinees: a 20 year follow up study. J Natl Cancer Inst 2009;101(19):1348-
55 
Chen HY, Juan CC, Ker CG. Laparoscopic liver surgery for patients with hepatocellular 
carcinoma. Ann Surg Oncol. 2008;15(3):800-806. 
Chen TW, Chu CM, Yu JC et al. Comparison of clinical staging systems in predicting 
survival of hepatocellular carcinoma patients receiving major or minor 
hepatectomy. Eur J Surg Oncol 2007;33(4):480-7 
Choi BI. Advances of imaging for hepatocellular carcinoma. Oncology 2010;78(suppl 1):46-
52 
Choi SB, Lee JG, Kim KS et al. The prognosis and survival analysis according to seven 
staging systems of hepatocellular carcinoma following curative resection. 
Hepatogastroenterology 2008;55:2140-5 
Cillo U, Bassanello M, Vitale A et al. The critical issue of hepatocellular carcinoma 
prognostic classification: Which is the best available? J Hepatol 2004;40:124-31 
Cillo U, Vitale A, Grigoletto F et al. Prospective validation of the Barcelona Clinic Liver 
cancer staging system. J Hepatol 2006;44:723-31  
Colli A, Fraquelli M, Casazza G et al. Accuracy of ultrasonography, spiral CT, magnetic 
resonance, and alpha feto-protein in the diagnosis of hepatocellular carcinoma: a 
systematic review. Am J Gastroenterol 2006;101(3):513-23 
Dagher I, Belli G, Fantini C, et al. Laparoscopic hepatectomy for hepatocellular carcinoma: a 
European experience. J Am Coll Surg. 2010;211:16-23 
Davila JA, Morgan RO, Shaib Y et al. Hepatitis C infection and the increasing incidence of 
hepatocellular carcinoma: a population-based study. Gastroenterology 
2004;127:1372-80 
Davis GL, Alter MJ, El-Serag HB, et al. Aging of hepatitis C virus-infected persons in the 
United States: a multiple cohort model of HCV prevalence and disease progression. 
Gastroenterology 2010;138(2):513-21 
Decans T, Roudot-Thoraval F, Bresson-Hadi, C, et al. Impact of Pretransplantation 
Transartierial Chemoembolization on Survival and Recurrence After Liver 
Transplantation for Hepatocellular Carcinoma. Liver Transpl 11 (2005): 767-775.  
Dohmen K. Many staging systems for hepatocellular carcinoma: Evolution from Child-
Pugh, Okuda to SLiDe. J Gastroenterol Hepatol 2004;19(11):1227-32 
www.intechopen.com
 
Liver Transplantation for Hepatocellular Carcinoma (HCC) 
 
297 
Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined 
effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J 
Cancer 1998;75(3):347-54 
Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of 
lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 
2002;155(4):323-31  
Dubay D, Sandroussi C, Sandhu L et al. Liver transplantation for advanced hepatocellular 
carcinoma using poor tumor differentiation on biopsy as an exclusion criteria. Ann 
Surg 2011;253:166-72 
El-Serag HB, Lau M, Eschbach K, et al. Epidemiology of hepatocellular carcinoma in 
Hispanics in the United States. Arch Intern Med 2007;167(18):1983-9 
El-Serag HB, Rudolph L. Hepatocellular carcinoma: Epidemiology and molecular 
carcinogenesis. Gastroenterology 2007;132(7):2557-76 
El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and 
hepatocellular carcinoma. Gastroenterology 2004;126:460-8 
Fan ST, Poon RT, Yeung C et al. Outcome after partial hepatectomy for hepatocellular cancer 
within the Milan criteria. Br J Surg 2011 Sep; 98 (9):1292-1300 
Figueras J, Jaurrieta E, Valls C et al. Survival after liver transplantation in cirrhotic patients 
with and without hepatocellular carcinoma: a comparative study. Hepatology 
1997;25(6):1485-9 
Forner A, Vilana R, Ayuso C et al. Diagnosis of hepatic nodules 20mm or smaller in 
cirrhosis: prospective validation of the noninvasive diagnostic criteria for 
hepatocellular carcinoma. Hepatology 2008;47(1):97-104 
Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis 
C virus infection. Hepatology 2001;34(4):809-16 
Golfieri R, Marini E, Bazzocchi A et al. Small (<or=3cm) hepatocellular carcinoma in 
cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row 
CT. Radiol Med 2009;114(8):1239-66 
Greene FL, Sobin LH. The staging of cancer: a retrospective and prospective appraisal. CA 
Cancer J Clin 2008;58(3):180-90 
Guglielmi A, Ruzzenente A, Pachera S et al. Comparison of seven staging systems in 
cirrhrotic patients with hepatocellular carcinoma in a cohort of patients who 
underwent radiofrequency ablation with complete response. Am J Gastroenterol 
2008;103:597-604 
Guiteau JJ, Cotton RT, Washburn WK et al. An early regional experience with expansion of 
Milan criteria for liver recipients. Am J Transpl 2010;10(9):2092-8 
Gursoy-Yuzugullu O, Yuzugullu H, Yilmaz M, et al. Aflatoxin genotoxicity is associated 
with a defective DNA damage response bypassing p53 activation. Liver Int 
2011;31(4):561-71 
Gurusamy KS, Pamecha V, Davidson BR. Piggy-back graft for liver transplantation. 
Cochrane Database Syst Rev 2011 Jan 19;(1) CD008258 
Hsu CY, Hsia CY, Huang YH, et al. Selecting an optimal staging system for hepatocellular 
carcinoma: comparison of 5 currently used prognostic models. Cancer 
2010;116(12):3006-14 
Huang GT, Sheu JC, Yang PM et al. Ultrasound-guided cutting biopsy for the diagnosis of 
hepatocellular carcinoma: a study based on 420 patients. J Hepatol 1996;25:334-8 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
298 
Idee JM, Port M, Dencausse A et al. Involvement of gadolinium chelates in the mechanism 
of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009;47(5):855-
69 
Iwatsuki S, Starzl TE, Sheahan DG et al. Hepatic resection versus transplantation for 
hepatocellular carcinoma. Ann Surg 1991;14(3):221-8 
Jang HJ, Kim TK, Burns PN et al. Enhancement patterns of hepatocellular carcinoma at 
contrast-enhanced US: comparison with histologic differentiation. Radiology 
2007;244(3):898-906 
Jang HJ, Kim TK, Wilson SR. Small nodules (1-2cm) in liver cirrhosis: characterization with 
contrast-enhanced ultrasound. Eur J Radiol 2009;72(3):418-24 
Kanwal F, Hoang T, Kramer JT et al. Increasing prevalence of HCC and cirrhosis in patients 
with chronic hepatitis C virus infection. Gastroenterology 2011;40(4):1182-88 
Katyal S, Oliver JH, Peterson MS et al. Extrahepatic metastases of hepatocellular carcinoma. 
Radiology 2000;216(3):698-703 
Kim KA, Kim MJ, Choi JY et al. Development of hepatocellular carcinoma in patients with 
absence of tumors on a prior ultrasound examination. Eur J Radiol 2011,  
 doi:10.1016/j.ejrad.2011.03.053 
Kim R, Aucejo F. Radiologic complete response with sirolimus and sorafenib in a 
hepatocellular carcinoma patient who relapsed after orthotopic liver 
transplantation.J Gastrointest cancer 2011 Mar ;42 (1):50-3 
Kitai S, Kudo M, Minami Y et al. A new prognostic staging system for hepatocellular 
carcinoma: value of the biomarker combined Japan Integrated Staging score. 
Intervirology 2008;51(suppl 1):86-94 
Koneru B, Teperman LW, Manzarbeitia C et al. A multicenter evaluation of utility of chest 
computer tomography and bone scan in liver transplant candidates with stage I 
and II hepatoma. Ann Surg 2005;241:622-8 
Kudo M, Chung H, Haji S et al. Validation of a new prognostic staging system for 
hepatocellular carcinoma: The JIS score compared with the CLIP scope. Hepatology 
2004;40:1396-1405 
Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellualr carcinoma (CLIP 
score): its value and limitations, and a proposal for a new staging system, the Japan 
Integrated Staging score (JIS score). J Gastroenterol 2003;38:207-15. 
Laurent A, Tayar C, Andréoletti M, et al. Laparoscopic liver resection facilitates salvage liver 
transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 
2009;16(3):310-4. 
Lee DH, Kim SH, Lee JM et al. Diagnostic performance of multidetector row computed 
tomography, superparamagnetic iron oxide-enhanced magnetic resonance 
imaging, and dual-contrast magnetic resonance imaging in predicting the 
appropriateness of a transplant recipient based on Milan criteria: correlation with 
histopathological findings. Invest Radiol 2009;44(6):311-21 
Lee JM, Trevisani F, Vilgrain V et al. Imaging diagnosis and staging of hepatocellular 
carcinoma. Liver Transpl 2011, doi:10.1002/lt.22369 
Lee KH, O’Malley ME, Haider MA et al. Triple-phase MDCT of hepatocellular carcinoma. 
Am J Roentgenol 2004;182(3):643-9 
Lee, F. Treatment of Hepatocellular Carcinoma in Cirrhosis: Locoregional Therapies for 
Bridging to Liver Transplant. Liver Transpl 13 (2007). 24-26. 
www.intechopen.com
 
Liver Transplantation for Hepatocellular Carcinoma (HCC) 
 
299 
Lencioni, R., Cioni, D., Crocetti, L., and Bartolozzi, C. “Percutaneous Ablation of 
Hepatocellular Carcinoma: State-of-the-Art.” Liver Transpl 10 (2004): 91-96. 
Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk 
assessment. Environ Health Perspect 2010;118:818-24 
Llovet JM, Bru C, Briux J. Prognosis of hepatocellular carcinoma: the BCLC stating 
classification. Semin Liver Dis 1999;19(3):329-38 
Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical 
hepatocellular carcinoma: rationale for the design and evaluation of therapeutic 
trials. Hepatology 1999;29(1):62-7 
Lu W, Dong J, Huang Z, et al. Comparison of four staging systems for Chinese patients with 
hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM, and 
CUPI. J Gastroenterol Hepatol 2008;23(12):1874-8 
Luca A, Caruso S, Milazzo M et al. Multidetector-row computer tomography (MDCT) for 
the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver 
transplantation: prevalence of radiological vascular patterns and histological 
correlation with liver explants. Eur Radiol 2010;20(4):898-907 
Maddala YK, Stadheim L, Andrews JC et al. Drop-out rates of patients with hepatocellular 
cancer listed for liver transplantation: outcome with chemoembolization. Liver 
Transpl 2004:10:449-455 
Majno, P., Mentha, G., and Toso, C. “Transplantation for Hepatocellular Carcinoma: 
Management of Patients on the Waiting List.” Liver Transpl 16 (2010): 2-11.  
Marrero JA, Fontana RJ, Barrat A et al. Prognosis of hepatocellular carcinoma: Comparison 
of 7 staging systems in an American cohort. Hepatology 2005;41:707-16 
Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for 
hepatocellualr carcinoma. Oncologist 2010;15(suppl 4):23-33 
Mazzaferro V, LLovet JM, Miceli R, et al.Predicting survival alter liver transplantation in 
patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, 
exploratory analysis. Lancet oncol 2009 Jan 10(1):35-43 
Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small 
hepatocellular carcinoma in patients with cirrhosis. N Eng J Med 1996;334(11)693-9 
Morris-Stiff G, Gomez D, de Liguori Carino N et al. Surgical management of hepatocellular 
carcinoma: is the jury still out ?. Surg Oncol 2009 Dec;18(4):298-321 
Nanashima A, Omagari K, Tobinaga S et al. Comparative study of survival of patients with 
hepatocellular carcinoma predicted by different staging systems using multivariate 
analysis. Eur J Surg Onc 2005;31(8):882-90 
Newell P, Toffanin S, Villanueva A, et al. Ras pathway activation in hepatocellular 
carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.J 
Hepatol 2009, Oct ; 51 (4): 725-33 
Nguyen KT, Marsh JW, Tsung A, et al. Comparative benefits of laparoscopic vs open hepatic 
resection: A critical appraisal. Arch Surg. 2011; 146(3):348-356. 
Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in 
hepatocellular carcinoma. Dig Liver Dis 2010;42(suppl 3):s206-14 
Park EJ, Lee JH, Yu GY et al. Dietary and genetic obesity promote liver inflammation and 
tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140:197-08 
Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 
2005;55(2):74-108 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
300 
Perz JF, Armstrong GL, Farrington LA et al. The contributions of hepatitis B virus and 
hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.  
J Hepatol 2006;45(4):529-38 
Pomfret EA, Washburn K, Wald C et al.Report of a national Conference on Liver Allocation 
in patients with hepatocellular carcinoma in the United States. Liver Transpl 
2010;16:262-278 
Pompili M, Mirante VG, Rondinara G et al. Percutaneous ablation procedures in cirrhotic 
patients with hepatocellular carcinoma submitted to liver transplantation: 
assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver 
Transpl 2005; 41:1130-1137 
Roberts, J., Vennok, A., Kerlan, R. et al. “Hepatocellular Carcinoma: Ablate and Wait Versus 
Rapid Transplantation.” Liver Transplantation 16 (2010): 925-929.  
Rockey DC, Caldwell SH, Goodman Z et al. Liver biopsy. Hepatology 2009;49(3):1017-44 
Ronzoni A, Artioli D, Scardina R et al. Role of MDCT in the diagnosis of hepatocellular 
carcinoma in patients with cirrhosis undergoing orthotopic liver transplantation. 
Am J Roentgenol 2007;189(4):792-8 
Rossi S, Ghittoni G, Ravetta V et al. Contrast-enhanced ultrasonography and spiral CT in 
detection and characterization of portal vein thrombosis complicating 
hepatocellular carcinoma. Eur Radiol 2008;18:1749-56 
Sakai T, Matsusaki T, Marsh JW et al. Comparison of surgical methods in liver 
transplantation: retrohepatic caval resection with veno-venous bypass (VVB) 
versus piggyback (PB) with VVB versus PB without VVB. Transpl Int 2010 
Dec;23(12):1247-58 
Schotman SN, De Man RA, Stoker J et al. Subcutaneous seeding of hepatocellular carcinoma 
after percutaneous liver biopsy. Gut 1999;45(4)625-6 
Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis 2011;15(2):323-
34 
Sheth H, Javed SS, Hilson AJW et al. Radioisotope bone scan in preoperative staging of 
hepatopancreatobiliary cancer. Br J Surg 2005;92(2):203-7 
Shi J, Zhu L, Liu S, et al. A meta-analysis of case-control studies on the combined effects of 
hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J 
Cancer 2005;92(3):607-12 
Si MS, Amersi F, Golish SR et al. Prevalence of metastases in hepatocellular carcinoma: risk 
factors and impact on survival. Am Surg 2003;69(10):879-85 
Silva MA, Hegab B, Hyde C et al. Needle track seeding following biopsy of liver lesions in 
the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 
2008;57(11):1592-6 
Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? 
J Hepatol 2011, doi:10.1016/jhep.2011.05.012 
Sood A, Midha V, Sood N. Needle track metastasis of primary liver carcinoma after 
percutaneous needle aspiration. Am J Gastroenterol 2002;97(3):765-6 
Sorrentino P, D’Angelo S, Tarantino L et al. Contrast-enhanced sonography versus biopsy 
for the differential diagnosis of thrombosis in hepatocellular carcinoma patients. 
World J Gastroenterol 2009;15(18):2245-51 
Sun JJ, Tsoi KK, Wong VW, et al. Meta-analysis: Treatment of hepatitis B infection reduces 
risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28(9):1067-77 
www.intechopen.com
 
Liver Transplantation for Hepatocellular Carcinoma (HCC) 
 
301 
Tan KC, Rela M, Ryder SD et al. Experience of orthotopic liver transplantation and hepatic 
resection for hepatocellular carcinoma of less than 8 cm in patients with cirrhosis. 
Br J Surg 1995;82:253-6 
Tanaka H, Imai Y, Hiramatsu N et al. Declining incidence of hepatocellular carcinoma in 
Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008;148(11):820-6 
The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for 
hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 
1998;28:751-5 
Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in 
chronic hepatitis C virus infection: a meta-analysis and meta-regression. 
Hepatology 2008;48(2):418-31 
Toso C, Merani S, Bigam DL et al. Sirolimus-based immunosuppression is associated with 
increased survival after liver transplantation for hepatocellular carcinoma. 
Hepatology, 2010 Apr; 51 (4):1237-43 
Trojan J, Schroeder O, Raedle J et al. Flourine-18 FDG positron emission tomography for 
imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94(11):3314-9 
Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system 
(CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the 
Liver Italian Program. Hepatology 2001;34:529-34 
United Network for Organ Sharing. Policies 3.6:organ distribution: allocation of livers. 
Available at http://www.unos.org 
Viera de Melo PS, Miranda LE, Batista LL et al. Orthotopic liver transplantation without 
venovenous bypass using the conventional and piggyback techniques. Transplant 
Proc 2011 May; 43(4): 1327-33  
Wang JH, Changchien CS, Hu TH et al. The efficacy of treatment schedules according to 
Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma: Survival 
analysis of 3892 patients. Eur J Cancer 2008;44:1000-6 
Wang Y, Speeg KV, Washburn WK et al. Sirolimus plus sorafenib in treating HCC 
recurrence after liver transplantation: a case report. World J Gastroenterol 2010 
Nov 21;16(43):5518-22 
Wen Xu et al. Progress and Prospects in cancer stem cell research in hepatocellular 
carcinoma. Chinese Journal of Cancer 28 (2009): 43 
Wigg, A., Palumbo, K., and Wigg, D. Radiotherapy for Hepatocellular carcinoma: Systemic 
review of radiobiology and modeling projects indicate reconsideration of its use. 
Journal of Gastroenterology and Hepatology 25 (2010): 664-617.  
Wolfort RM, Papillion PW, Turnage RH et al. Role of FDG-PET in the evaluation and 
staging of hepatocellular carcinoma with comparison to tumor size, AFP level and 
histologic grade. Int Surg 2010;95(1):67-75 
Wree A, Kahraman A, Gerken G, et al. Obesity affects the liver- the link between adipocytes 
and hepatocytes. Digestion 2011;83:124-33 
Xu LB, Wang J, Liu C et al. Staging systems for predicting survival of patients with 
hepatocellular carcinoma after surgery. World J Gastroenterol 2010;16(41)5257-62 
Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk for hepatocellular 
carcinoma. N Engl J Med 2002;347(3):168-74 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
302 
Yao FY, Ferrel L, Bass NB et al. Liver Transplantation for Hepatocellular carcinoma: 
expansion of the tumor size limits does not adversely impact survival.Hepatology 
2001; 33:1394-1403 
Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: 
expansion fo the tumor size limits does not adversely impact survival. Hepatology 
2001;33:1394-1403 
Yao FY, Xiao L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: validation 
of the UCSF-expanded criteria based on preoperative imaging. Am J Transpl 
2007;7(11):2587-96 
Yao F, Kerlan R, Hirose R, et al. Excellent Outcome Following Down-staging of 
Hepatocellular Carcinoma prior to Liver Transplantation: An Intention-to-treat 
Analysis. Hepatology (2008): 819-827. 
Yoon KT, Kim JK, Kim do Y et al. Role of 18-fluorodeoxyglucose positron emission 
tomography in detecting extrahepatic metastasis in pretreatment staging of 
hepatocellular carcinoma. Oncology 2007;(suppl 1):104-10 
Yoshizawa H. Hepatocellular carcinoma associated wth hepatitis C virus infection in Japan: 
projection to the other countries in the foreseeable future. Oncology 2002;62(suppl 
1):8-17 
Yu MW, Yang YC, Yang SY. Hormonal markers and hepatitis B virus-related hepatocellular 
carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 
2001;93(21):1644-51 
www.intechopen.com
Liver Transplantation - Basic Issues
Edited by Prof. Hesham Abdeldayem
ISBN 978-953-51-0016-4
Hard cover, 418 pages
Publisher InTech
Published online 15, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book covers a wide spectrum of topics including history of liver transplantation, ischemia-reperfusion
injury, immunology of liver transplantation, viral hepatitis and liver transplantation, other indications for liver
transplantation, prognostic factors and perioperative period. The authors of the chapters are experts in their
respective fields. They are proponents covering different aspects of liver transplantation and come from many
centers across the world. The interdisciplinary approach and the authority of the contributors resulted in a
valuable reference to anyone interested in developing a global view in liver transplantation including medical
students, residents, fellows, nurses, and practicing physicians and surgeons as well as researchers in the field
of liver transplantation.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Alejandro Mejia, Hector Nazario and Parvez Mantry (2012). Liver Transplantation for Hepatocellular
Carcinoma (Hcc), Liver Transplantation - Basic Issues, Prof. Hesham Abdeldayem (Ed.), ISBN: 978-953-51-
0016-4, InTech, Available from: http://www.intechopen.com/books/liver-transplantation-basic-issues/liver-
transplantation-for-hepatocellular-carcinoma-hcc-
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
